Project Name: SDS MyHealthcare Limited – Enhanced Lipid Specialist Review Project  

Project Summary:

The main objective of the CWP is to improve the quality of care for patients and support the early identification, review, and medical optimisation of patients with atherosclerotic cardiovascular disease (ASCVD) in response to the needs of the CW Partner. The project is aiming to achieve:-

  • Identification of sub-optimally treated ASCVD patients at the highest risk of cardiovascular events in primary care, who are not achieving lipid targets as specified in national guidance and/or local guidelines
  • Identification of ASCVD patients at the highest risk of cardiovascular events in primary care, who have previously not tolerated or refused alternative lipid modification therapies  
  • Review of treatment options and decision on next steps in collaboration with ASCVD patients
  • Counsel and optimise ASCVD patients where appropriate  
  • Early identification of at-risk patients who have not had intervention in their health and wellbeing 
  • Identification of ASCVD patients, following risk assessment review, of ASCVD patients who are sub-optimally treated  
  • On-going ASCVD patients support and annual review to ensure CVD outcomes improve equitably

Planned Milestones:

  1. Project Kick Off meeting, Collection of baseline data, in line with the measure of success, confirmation of clinical and operational pathway, policy and protocol creation, and readiness to begin the clinical activity
  2. Collection of 3 months clinical activity data
  3. Collection of 6 months clinical activity data
  4. Collection of 9 months clinical activity data
  5. Collection of 12 months clinical activity data
  6. Collection of 15 months clinical activity data
  7. Collection of 18 months clinical activity data
  8. Development of business case
  9. Analysis of project data, and submission of Final Project Report

Expected Benefits:

Anticipated benefits for patients:

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.  
  • Enhanced experience and counselling around ASCVD with ongoing management of the condition.  
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events 
  • Easier access to lipid management care closer to home in the PCN setting 
  • The additional capacity will provide additional time and support from PCN HCP with their lipid management, focusing on patients who may have previously not attended GP appointment or been lost to follow-up. Thus, levelling health inequalities within the PCN

Anticipated benefits for partner organisation:

  • Increased proportion of ASCVD patients reviewed by primary care  
  • Increased proportion of ASCVD patients receiving expert and timely review closer to home 
  • Reduction in ASCVD referral rates to secondary care 
  • Increased proportion of patients receiving guideline-directed pharmacotherapy 
  • Insight into benefits of primary care pharmacist led lipid management clinics in primary care and demonstration of benefit via development of business case for substantive funding 
  • Support aligned to NHS Long Term Plan, CDVPREVENT, and Network Contract DES 

Anticipated benefits for Novartis:

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine 
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life by supporting high quality Collaborative Working with the NHS which addresses the problem of health inequalities 
  • Ethical, professional, and transparent relationship between Novartis and the NHS

Start Date & Duration: 

Start Date: Dec 2022

Duration: 22 month project (18 months of clinical activity)